Advertisement
China’s private sector
BusinessChina Business

Insilico teams up with US firm to build AI models predicting disease decades ahead

Tie-up combines Hong Kong-listed Insilico Medicine’s algorithms with Human Longevity’s genomic data to advance personalised health research

2-MIN READ2-MIN
2
Listen
The global longevity market, fuelled by an ageing population and rising consumption demand, is currently valued at US$5.3 trillion, according to a UBS report. Photo: Shutterstock
Julie Zhang
Hong Kong-listed artificial intelligence drug-discovery company Insilico Medicine has struck a collaboration with US-headquartered Human Longevity to co-develop what they describe as “the industry’s first large-scale” AI foundation models capable of predicting diseases – such as cancer – decades before clinical symptoms appear.

The partnership was announced as the global longevity market, fuelled by an ageing population and rising consumption demand, was valued at about US$5.3 trillion and projected to reach US$8 trillion by 2030, according to a recent UBS report.

Insilico founder and CEO Alex Zhavoronkov, in a written reply, framed the tie-up as the world’s two leading companies in the AI and longevity fields joining forces, adding they “have developed a conceptually new type of personal longevity AI that will not only let you live longer, but also help you and others discover new longevity drugs that work for everyone.”

Neither party disclosed the exact investment amount. They described the arrangement as “a multimillion-dollar AI co-development collaboration”.

Select Voice
Select Speed
1x
AI-generated voice